Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo

Atherosclerosis

Volumn 202, Issue 1, 2009, Pages 76-83

  Dasu, Mohan R ^a   Riosvelasco, Andrea C ^a   Jialal, Ishwarlal ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin receptor blocker; Inflammation; LPS; Monocytes; Nuclear factor kappa B; Toll like receptors

Indexed keywords

ATORVASTATIN; CANDESARTAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; LIPOPEPTIDES; MALE; MICE; MICE, INBRED C57BL; MONOCYTES; PHENOTYPE; REACTIVE OXYGEN SPECIES; TETRAZOLES; TOLL-LIKE RECEPTORS;

EID: 57649155518     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.04.010     Document Type: Article

References (44)

1. Miggin S.M., and O'Neill L.A. New insights into the regulation of TLR signaling. J Leukoc Biol 80 2 (2006) 220-226
2. Verstak B., Hertzog P., and Mansell A. Toll-like receptor signaling and the clinical benefits that lie within. Inflamm Res 56 1 (2007) 1-10
3. O'Neill L.A. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol 3 4 (2003) 396-403
4. Trinchieri G., and Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 7 3 (2007) 179-190
5. Edfeldt K., Swedenborg J., Hansson G.K., and Yan Z.Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105 (2002) 1158-1161
6. Xu X.H., Shah P.K., Faure E., et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 104 (2001) 3103-3108
7. Mullick A.E., Tobias P.S., and Curtiss L.K. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 115 11 (2005) 3149-3156
8. Li H., and Sun B. Toll-like receptor 4 in atherosclerosis. J Cell Mol Med 11 1 (2007) 88-95
9. Shinohara M., Hirata K.I., Yamashita T., et al. Local overexpression of Toll-like receptors at the vessel wall induces atherosclerotic lesion formation. Synergism of TLR2 and TLR4. Arterioscler Thromb Vasc Biol September 13 (2007) [Epub ahead of print]
10. Devaraj S., Dasu M.R., Rockwood J., et al. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 93 2 (2008) 578-583
11. Dzau V.J. Theodore Cooper Lecture. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37 (2001) 1047-1052
12. Nickenig G., and Harrison D.G. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis. Part I. Oxidative stress and atherogenesis. Circulation 105 3 (2002) 393-396
13. Nickenig G. Central role of the AT(1)-receptor in atherosclerosis. J Hum Hypertens 16 3 (2002) S26-S33
14. Suzuki Y., Ruiz-Ortega M., Lorenzo O., et al. Inflammation and angiotensin II. Int J Biochem Cell Biol 35 6 (2003) 881-900
15. Dahlof B., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 9311 (2002) 995-1003
16. Demers C., et al. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA 294 14 (2005) 1794-1798
17. Mehta J.L. Modulation of arterial thrombosis by angiotensin-converting enzyme inhibition and angiotensin II type 1-receptor blockade. Am J Cardiol 82 10A (1998) 53S-56S
18. Heeneman S., Sluimer J.C., and Daemen M.J.A.P. Angiotensin converting enzyme and vascular remodeling. Circ Res 101 (2007) 441-454
19. Tsutamoto T., Wada A., Maeda K., et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 35 3 (2000) 714-721
20. Donaire J.A., and Ruilope L.M. Angiotensin receptor blockade in diabetic renal disease-focus on candesartan. Diabetes Res Clin Pract 76 1 (2007) S22-S30
21. Ghiadoni L., Virdis A., Magagna A., Taddei S., and Salvetti A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 35 1 Pt 2 (2000) 501-506
22. Koh K.K., Ahn J.Y., Han S.H., et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 42 5 (2003) 905-910
23. Igarashi M., Hirata A., Yamaguchi H., et al. Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats. Hypertension 38 6 (2001) 1255-1259
24. Koh K.K., Quon M.J., Han S.H., et al. Vascular and metabolic effects of candesartan: insights from therapeutic interventions. J Hypertens Suppl 24 1 (2006) S31-S38
25. Dohi Y., Ohashi M., Sugiyama M., et al. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res 26 9 (2003) 691-697
26. Koh K.K., Quon M.J., Han S.H., et al. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 108 1 (2006) 96-100
27. Devaraj S., Glaser N., Griffen S., et al. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 55 3 (2006) 774-779
28. Dasu M.R., Devaraj S., Du Clos T.W., and Jialal I. The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res 48 3 (2007) 509-512
29. Devaraj S., Venugopal S.K., Singh U., and Jialal I. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase C-α and -β. Diabetes 54 (2005) 85-91
30. Dasu M.R., Devaraj S., and Jialal I. High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab 293 1 (2007) E337-E346
31. Matsuguchi T., Musikacharoen T., Ogawa T., and Yoshikai Y. Gene expressions of Toll-like receptor 2, but not Toll-like receptor 4, is induced by LPS and inflammatory cytokines in mouse macrophages. J Immunol 165 (2000) 5767-5772
32. Medvedev A.E., Kopydlowski K.M., and Vogel S.N. Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and Toll-like receptor 2 and 4 gene expression. J Immunol 164 (2000) 5564-5574
33. Niessner A., Steiner S., Speidl W.S., et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 189 2 (2006) 408-413
34. Methe H., Kim J.O., Kofler S., Nabauer M., and Weis M. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol 25 7 (2005) 1439-1445
35. Takeda K., Kaisho T., and Akira S. Toll-like receptors. Annu Rev Immunol 21 (2003) 335-376
36. Uematsu S., and Akira S. Toll-like receptors and innate immunity. J Mol Med 84 9 (2006) 712-725
37. Kawai T., and Akira S. TLR signaling. Cell Death Differ 13 5 (2006) 8156-8825
38. Kawai T., Adachi O., Ogawa T., Takeda S., and Akira S. Unresponsiveness of MyD88 deficient mice to endotoxin. Immunity 11 1 (1999) 115-122
39. Stoll L.L., Denning G.M., and Weintraub N.L. Endotoxin, TLR4 signaling and vascular inflammation: potential therapeutic targets in cardiovascular disease. Curr Pharm Des 12 32 (2006) 4229-4245
40. Mullick A.E., Tobias P.S., and Curtiss L.K. Toll-like receptors and atherosclerosis: key contributors in disease and health?. Immunol Res 34 3 (2006) 193-209
41. Michelsen K.S., Wong M.H., Shah P.K., et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 101 29 (2004) 10679-10684
42. Liu X., Ukai T., Yumoto H., et al. Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis April 25 (2007) [Epub ahead of print]
43. Creely S.J., McTernan P.G., Kusminski C.M., et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 292 3 (2007) E740-E747
44. Fazio S., and Linton M.F. The inflamed plaque: cytokine production and cellular cholesterol balance in the vessel wall. Am J Cardiol 88 2A (2001) 12E-15E